VR-CAR

VR-CAR is an engineered Chimeric Antigen Receptor (CAR) T cell therapy designed to overcome the limitations of conventional CAR T cells in treating solid tumors. It incorporates synthetic 'velocity receptors' (VRs) that bind to key inflammatory cytokines such as IL5, IL8, and TNFα. This binding amplifies autocrine secreted cytokines, maintaining a self-propelled, highly migratory state in the T cells, which enhances their ability to infiltrate dense tumor cores. The CAR component of VR-CAR T cells retains its antigen-specific binding to cancer cells, eliciting anti-tumor responses. This dual mechanism aims to improve tumor penetration and efficacy against solid tumors, which have historically been challenging for CAR T cell therapies due to limited infiltration capacity. Preclinical studies have shown that VR-CAR T cells can significantly attenuate tumor growth and extend overall survival in various mouse models of human cancers, including lung, ovarian, and pancreatic tumors.

Other names

VR-CAR T cells